0500 GMT - Raffles Medical Group is likely to benefit from the further reopening of Singapore's borders, given it is the sole provider of Covid-19 polymerase chain reaction tests at the country's Changi Airport, RHB Research says. The conversion of the Connect@Changi business facility into a Covid-19 community-care facility should also support near-term revenue growth, the broker says. The likely return of walk-in patients to clinics and inflow of more foreign patients into Singapore could further help, RHB Research says. It keeps a buy call on Raffles Medical and raises the target price to S$1.65 from S$1.45. Shares fall 1.3% to S$1.46. (yongchang.chin@wsj.com)
Raffles Medical Set to Gain as Singapore Further Opens Borders -- Market Talk
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.